Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study
| Autor: | Cato Mørk, L Molin, S. Davidsson, H. Zachariae, Bardur Sigurgeirsson, Kirsti Blomqvist, Robert Zachariae |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Complementary Therapies
Male Administration Topical location.country Anti-Inflammatory Agents Etretinate Dermatology Norwegian Acitretin Danish location Quality of life Calcitriol Psoriasis Surveys and Questionnaires medicine Humans PUVA Therapy Response rate (survey) Analysis of Variance business.industry General Medicine Anthralin Middle Aged medicine.disease language.human_language Europe Methotrexate Health Care Surveys language Cyclosporine Female Steroids Faeroe Islands Dermatologic Agents business Demography medicine.drug |
| Zdroj: | Zachariae, H, Zachariae, R, Blomqvist, K, Davidsson, S, Molin, L, Mork, C & Sigurgeirsson, B 2001, ' Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study ' Acta Dermato Venereologica, vol. 81 (2), pp. 116-121 . |
| ISSN: | 0001-5555 |
| Popis: | was almost twice the average. While 14.2% of Danish members psoriasis associations from Denmark, Finland, Norway and Sweden, had received grenz-rays within the last week only 0.1% of the and to all members acknowledged the associations from Iceland and Finns had been given the same treatment. Psoralen plus ultravi- the Faeroe Islands. There were 1,356 responders (67.8%) from olet A (PUVA) was being usedby 13.1% of the Finnishpsoriatics Denmark, 1,125 (56.3%) from Finland, 451 (40.0%) from Iceland, 903 (45.2%) from Norway, 1,828 (45.7%) from Sweden and 76 (44.0%) compared with 3.8% of Danes, while PUVA was almost non- from the Faeroe Islands, yielding a total of 5,739psoriatics. The existent on the Faeroe Islands. The use of non-PUVA photo- percentages in parentheses represent response rates, with the average therapy was highest in Norway and Sweden. Almost 10% of the response rate being 50.2%. Patients were excluded if they were under Danes were presently on methotrexate, which was used far more 18 years old, and only patients who had had their diagnosis of than etretinate/acitretin or cyclosporine. In contrast, Finnish psoriasis made or cone rmed by a dermatologist were included in the study. The age and sex variation within the groups is shown in Table I, patients more often received etretinate than other systemic together with the duration of psoriasis. No diŒerence in theproportion agents, and in Iceland there was a higher present use of of men and women was found between countries (v 2=6.7; ns), with cyclosporine than of etretinate. The popularity of alternative more women than men participating in the survey. There were therapies was highest in Iceland, where 26.6% had taken such signiecant diŒerences between countries with respect to age (F 5,723 = 57.1; p< 0.001), disease duration (F 5,723 =53.9; p< 0.001) and disease medication during the last week. The results of the study suggest severity (v 2=113.5; p< 0.001). The Finnish and Swedish samples were that diŒerent treatment patterns should be taken into considera- older, had longer disease duration and reported less severe psoriasis tion when discussing the prognosis of psoriasis in diŒerent than the other samples. The Norwegian sample had the highest |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|